FDA's Temple Discusses Measuring Efficacy When Mean Effect Is Limited

The distribution of positive results for individual patients, as well as a drug's mean benefit across the population of treated patients in a clinical trial, can be useful in assessing efficacy, CDER Deputy Director for Clinical Science Bob Temple indicated March 2 during a meeting on clinical trials for pulmonary arterial hypertension

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet